Adenocarcinoma risk in patients registered with Polish Barrett's Oesophagus Registry. Issue 1 (21st December 2016)

• Record Type: Journal Article
• Authors: Januszewicz, Władysław; Kamiński, Michał F.; Wieszczy, Paulina; Wrońska, Ewa; Bielasik, Andrzej; Wojciechowska, Urszula; Didkowska, Joanna; Orłowska, Janina; Reguła, Jarosław
• Is Part Of: Diseases of the esophagus. Volume 30:Issue 1(2017)
• Page Start: 1
• Page End: 6
• Publication Date: 2016-12-21
• Subjects: adenocarcinoma -- Barrett's oesophagus -- low grade dysplasia -- neoplasia -- registry; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1111/dote.12483
• Languages: English
• ISSNs: 1120-8694

Abstract

SUMMARY: Barrett's Oesophagus (BO) is a complication of chronic gastro-oesophageal reflux disease (GORD) and is a major risk factor for oesophageal adenocarcinoma. Current guidelines are based on data showing a 0.5% annual malignancy progression rate. The Polish Barrett's Oesophagus Registry (POBOR) was established to characterize Polish patients with BO and estimate the risk of malignant progression. POBOR was established in 1999 after a dedicated training of endoscopists and histopathologists. Physicians registered patients using a dedicated registry form. After excluding patients known to have endoscopic treatment for BO, follow-up <1 year and adenocarcinoma found at index endoscopy we have linked patients personal identification numbers (PESEL) with the National Cancer Registry to identify those with a diagnosis of oesophageal or gastric cardia adenocarcinoma. In total, 843 patients were registered [609 men (72.2%), male to female ratio 2.6:1] with median age at diagnosis of 56 years (IQR:47-67). Long segment BE was found at index endoscopy in 294 patients (39.4%) whereas low grade dysplasia in 147 (17.4%). 112 patients (13.3%) fulfilled the exclusion criteria and the remaining 731 were followed for a median of 9.8 years (IQR: 9.3–10.0). After 6779 patient-years, 6 adenocarcinomas were diagnosed yielding an incidence rate of 0.89 per 1000 patients–years (95% confidence interval [CI 0.40–1.97]) which corresponds to annual malignancy progression rate of less than 0.1%. The malignancy rate in patients with low grade dysplasia was 3.70 per 1000 patient-years (95% CI 1.39-9.85). In Polish BO patients the risk of malignant progression was lower than previously reported. It was notably higher in patients with low grade dysplasia than in those with no dysplasia at index endoscopy, which may warrant strict surveillance in these patients.